PCM
FATE icon

Pentwater Capital Management’s Fate Therapeutics FATE Stock Holding History

Pentwater Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20,000
Closed -$311K – 161
2019
Q3 		$311K Buy
+20,000
New +$383K ﹤0.01% 140

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Pentwater Capital Management's FATE Position: Q4 2019 in Review

Pentwater Capital Management sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 20,000 shares — an estimated $311K sold.

Pentwater Capital Management first reported a position in FATE in Q3 2019 and held it in 1 quarter. The position peaked at $311K in Q3 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • Pentwater Capital Management reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Pentwater Capital Management sold 20,000 Fate Therapeutics shares in Q4 2019, an estimated $311K.
  • Pentwater Capital Management first reported a position in Fate Therapeutics in Q3 2019 and held it in 1 quarter.
  • Pentwater Capital Management's Fate Therapeutics position peaked at $311K in Q3 2019.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Pentwater Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.